Literature DB >> 762611

Cell-mediated immunity to varicella-zoster virus infection in subjects with lymphoma or leukemia.

P A Patel, S Yoonessi, J O'Malley, A Freeman, A Gershon, P L Ogra.   

Abstract

Normal subjects and patients with lymphoma or leukemia were tested for the levels of lymphocytes, E-rosette--forming T-cells, serum and vesicle fluid interferon, and specific in vitro proliferative response to varicella-zoster antigen after clinical varicella or herpes zoster illness. The effect of polyinosinic acid/polycytidilic acid on the immune response was also evaluated. The development of VZ specific cell-mediated response in normal subjects was characterized by intense proliferative activity eight to ten days after the onset of illness, with significant decline 70 to 80 days later. The responses in subjects with lymphoma or leukemia were much lower. Few subjects with chickenpox or zoster with lymphoma or leukemia died during the infection. Death was associated with significant depletion of E-rosette--forming T-cells, and grossly deficient specific cellular response to VZ antigen. Treatment with Poly IC frequently induced elevations in serum as well as vesicle fluid interferon levels, and increased the proliferative activity of lymphocytes against VZ antigen.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 762611     DOI: 10.1016/s0022-3476(79)80828-8

Source DB:  PubMed          Journal:  J Pediatr        ISSN: 0022-3476            Impact factor:   4.406


  10 in total

1.  Varicella-zoster virus-specific cytotoxic T lymphocytes (Tc): detection and frequency analysis of HLA class I-restricted Tc in human peripheral blood.

Authors:  J K Hickling; L K Borysiewicz; J G Sissons
Journal:  J Virol       Date:  1987-11       Impact factor: 5.103

2.  Processing and presentation of cell-associated varicella-zoster virus antigens by human monocytes.

Authors:  O Pontesilli; P Carotenuto; M J Levin; D Suez; A R Hayward
Journal:  Clin Exp Immunol       Date:  1987-10       Impact factor: 4.330

3.  Use of bone marrow fibroblasts to prepare targets for an HLA restricted-cytotoxicity assay system.

Authors:  R A Bowden; L McGavren; A R Hayward; M J Levin
Journal:  J Clin Microbiol       Date:  1984-10       Impact factor: 5.948

4.  Cellular and humoral immunity in the pathogenesis of recurrent herpes viral infections in patients with lymphoma.

Authors:  A M Arvin; R B Pollard; L E Rasmussen; T C Merigan
Journal:  J Clin Invest       Date:  1980-04       Impact factor: 14.808

5.  Reduced cellular immunity to varicella zoster virus during treatment for acute lymphoblastic leukemia of childhood: in vitro studies of possible mechanisms.

Authors:  R H Giller; R A Bowden; M J Levin; L J Walker; D G Tubergen; A R Hayward
Journal:  J Clin Immunol       Date:  1986-11       Impact factor: 8.317

6.  Lysis of varicella zoster virus infected cells by lymphocytes from normal humans and immunosuppressed pediatric leukaemic patients.

Authors:  R A Bowden; M J Levin; R H Giller; D G Tubergen; A R Hayward
Journal:  Clin Exp Immunol       Date:  1985-05       Impact factor: 4.330

7.  Human polymorphonuclear leukocyte-mediated cytotoxicity against varicella-zoster virus-infected fibroblasts.

Authors:  T Ihara; S E Starr; M Ito; S D Douglas; A M Arbeter
Journal:  J Virol       Date:  1984-07       Impact factor: 5.103

8.  Decrease of the lymphoproliferative response to varicella-zoster virus antigen in the aged.

Authors:  R Berger; G Florent; M Just
Journal:  Infect Immun       Date:  1981-04       Impact factor: 3.441

Review 9.  Recognition and treatment of shingles.

Authors:  A F Nikkels; G E Piérard
Journal:  Drugs       Date:  1994-10       Impact factor: 9.546

10.  Viral load, clinical disease severity and cellular immune responses in primary varicella zoster virus infection in Sri Lanka.

Authors:  Gathsaurie Neelika Malavige; Louise Jones; S D Kamaladasa; A Wijewickrama; S L Seneviratne; Antony P Black; Graham S Ogg
Journal:  PLoS One       Date:  2008-11-21       Impact factor: 3.240

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.